New York State Grants Approval for IGeneX’s Newly Developed Tick-Borne Relapsing Fever (TBRF) ImmunoBlot Tests
[CanLyme Note: New York State has one of the strictest certification and approval processes in North America for laboratory tests. Canadian medical authorities have done nothing but lie about, criticize and malign Igenex for many years based upon opinion not science, simply because Canadians were turning to Igenex for better testing. Igenex has helped thousands of sick Canadians get their life back after the Canadian detection methods failed them. Canadian health authorities federal and provincially have intentionally continued to provide inadequate testing for tick-borne disease, have ignored reams of published evidence, have engaged in fear-mongering regarding effective treatment, and have mocked Lyme patients and their experts calling them mentally unstable and pseudo-scientists.]
TBRF ImmunoBlots (IgM and IgG) represent a quantum leap in testing for tick-borne diseases, particularly for patients with Lyme-like symptoms
October 8th, 2019
MILPITAS, Calif., Oct. 8, 2019 /PRNewswire/ — The Division of Laboratories of the Department of Health of the State of New York has approved IGeneX’s newly developed Tick-Borne Relapsing Fever (TBRF) ImmunoBlots (IgM and IgG), making them immediately available to New York practitioners.
Until recently, diagnostic tests for TBRF have been grossly insensitive and have not been able to detect many of the ever-growing list of species and strains of TBRF Borrelia carried by hard and soft ticks. The new IGeneX ImmunoBlots overcome these obstacles with the ability to detect antibodies to TBRF Borrelia species including, but not limited to, B. hermsii, B. miyamotoi, and B. turicatae.